• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个整合了前列腺癌临床、组学和特征的协调资源。

A harmonized resource of integrated prostate cancer clinical, -omic, and signature features.

机构信息

Department of Mathematics and Statistics, University of Turku, Turku, Finland.

Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

出版信息

Sci Data. 2023 Jul 5;10(1):430. doi: 10.1038/s41597-023-02335-4.

DOI:10.1038/s41597-023-02335-4
PMID:37407670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10322899/
Abstract

Genomic and transcriptomic data have been generated across a wide range of prostate cancer (PCa) study cohorts. These data can be used to better characterize the molecular features associated with clinical outcomes and to test hypotheses across multiple, independent patient cohorts. In addition, derived features, such as estimates of cell composition, risk scores, and androgen receptor (AR) scores, can be used to develop novel hypotheses leveraging existing multi-omic datasets. The full potential of such data is yet to be realized as independent datasets exist in different repositories, have been processed using different pipelines, and derived and clinical features are often not provided or  not standardized. Here, we present the curatedPCaData R package, a harmonized data resource representing >2900 primary tumor, >200 normal tissue, and >500 metastatic PCa samples across 19 datasets processed using standardized pipelines with updated gene annotations. We show that meta-analysis across harmonized studies has great potential for robust and clinically meaningful insights. curatedPCaData is an open and accessible community resource with code made available for reproducibility.

摘要

基因组和转录组数据已经在广泛的前列腺癌 (PCa) 研究队列中生成。这些数据可用于更好地描述与临床结果相关的分子特征,并在多个独立的患者队列中检验假设。此外,衍生特征,如细胞成分估计、风险评分和雄激素受体 (AR) 评分,可用于利用现有多组学数据集提出新的假设。由于独立数据集存在于不同的存储库中,使用不同的管道进行了处理,并且衍生的和临床特征通常未提供或未标准化,因此此类数据的全部潜力尚未实现。在这里,我们介绍了经过整理的 PCaData R 软件包,这是一个经过协调的数据资源,代表了来自 19 个数据集的 >2900 个原发性肿瘤、>200 个正常组织和 >500 个转移性 PCa 样本,这些数据集使用标准化管道进行了处理,并使用更新的基因注释进行了协调。我们表明,经过协调的研究的荟萃分析具有产生稳健且具有临床意义的见解的巨大潜力。 curatedPCaData 是一个开放且可访问的社区资源,提供了可重现性的代码。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/95f176fd5311/41597_2023_2335_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/a2906f16f50f/41597_2023_2335_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/8a701c7a9146/41597_2023_2335_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/95f176fd5311/41597_2023_2335_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/a2906f16f50f/41597_2023_2335_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/8a701c7a9146/41597_2023_2335_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91ae/10322899/95f176fd5311/41597_2023_2335_Fig3_HTML.jpg

相似文献

1
A harmonized resource of integrated prostate cancer clinical, -omic, and signature features.一个整合了前列腺癌临床、组学和特征的协调资源。
Sci Data. 2023 Jul 5;10(1):430. doi: 10.1038/s41597-023-02335-4.
2
curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource.精心整理的前列腺癌数据:在一个精心整理且协调一致的前列腺癌数据资源中整合临床、基因组和特征数据。
bioRxiv. 2023 Jan 19:2023.01.17.524403. doi: 10.1101/2023.01.17.524403.
3
Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.基质基因表达可预测转移性原发性前列腺癌。
Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.
4
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.TMEFF2 调控的细胞周期相关基因特征可预测前列腺癌的复发风险。
BMC Cancer. 2019 May 6;19(1):423. doi: 10.1186/s12885-019-5592-6.
5
Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.神经内分泌前列腺癌和原发性小细胞前列腺癌的基因表达特征。
BMC Cancer. 2017 Nov 13;17(1):759. doi: 10.1186/s12885-017-3729-z.
6
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes.前列腺癌基因表达数据的荟萃分析确定了一种富含糖基化酶的新型鉴别特征。
BMC Med Genomics. 2014 Dec 31;7:513. doi: 10.1186/s12920-014-0074-9.
7
Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.良性雄激素受体转录组表达的降低是局限性前列腺癌进展的一个标志。
Oncotarget. 2016 May 24;7(21):31384-92. doi: 10.18632/oncotarget.8915.
8
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.原发性前列腺癌转录组特征类似于前列腺小细胞神经内分泌癌。
Int J Cancer. 2019 Dec 15;145(12):3453-3461. doi: 10.1002/ijc.32430. Epub 2019 Jun 10.
9
Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.ETS 融合阴性前列腺癌中雄激素受体的独特转录谱。
Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.
10
Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.局部和转移性前列腺癌中神经肽 Y 表达的转录组和临床特征:具有临床意义的新型前列腺癌亚型的鉴定。
Eur Urol Oncol. 2019 Jul;2(4):405-412. doi: 10.1016/j.euo.2019.05.001. Epub 2019 Jun 2.

引用本文的文献

1
Systems biology successes and areas for opportunity in prostate cancer.系统生物学在前列腺癌中的成功案例与机遇领域
Endocr Relat Cancer. 2025 Aug 20;32(8). doi: 10.1530/ERC-25-0067. Print 2025 Aug 1.
2
ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.ProstaMine:一种用于识别与前列腺癌侵袭性相关的亚型特异性共改变的生物信息学工具。
Front Pharmacol. 2024 May 1;15:1360352. doi: 10.3389/fphar.2024.1360352. eCollection 2024.

本文引用的文献

1
DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update).DAVID:一个用于基因列表功能富集分析和功能注释的网络服务器(2021 更新)。
Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221. doi: 10.1093/nar/gkac194.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.
前列腺癌中的肿瘤微环境:迈向用于诊断、预后和治疗开发的新型分子生物标志物的鉴定
Front Genet. 2021 Mar 26;12:652747. doi: 10.3389/fgene.2021.652747. eCollection 2021.
4
Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer.微血管内皮细胞数量与结直肠癌化疗反应及预后相关。
Cancers (Basel). 2021 Mar 23;13(6):1477. doi: 10.3390/cancers13061477.
5
Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.黑人男性局部前列腺癌中富含浆细胞,且与改善预后相关。
Nat Commun. 2021 Feb 10;12(1):935. doi: 10.1038/s41467-021-21245-w.
6
Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.促进细胞增殖、细胞周期进程和糖酵解:糖代谢相关基因可作为前列腺癌的预后标志物。
Prostate. 2021 Feb;81(3):157-169. doi: 10.1002/pros.24092. Epub 2020 Dec 18.
7
Multiomic Integration of Public Oncology Databases in Bioconductor.公共肿瘤学数据库的 Bioconductor 多组学整合。
JCO Clin Cancer Inform. 2020 Oct;4:958-971. doi: 10.1200/CCI.19.00119.
8
Visualizing and interpreting cancer genomics data via the Xena platform.通过Xena平台可视化和解读癌症基因组学数据。
Nat Biotechnol. 2020 Jun;38(6):675-678. doi: 10.1038/s41587-020-0546-8.
9
The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer.长链非编码RNA TAPIR-1和-2在前列腺癌中作为诊断标志物和潜在治疗靶点的作用
Cancers (Basel). 2020 Apr 30;12(5):1122. doi: 10.3390/cancers12051122.
10
Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data.免疫去卷积:一个用于从批量 RNA 测序数据中估计免疫细胞分数的计算方法的统一访问的 R 包。
Methods Mol Biol. 2020;2120:223-232. doi: 10.1007/978-1-0716-0327-7_16.